Celgene and Bristol-Myers are 2013 stock market winners
This article was originally published in Scrip
Celgene’s stock outperformed all the biotech company’s big rivals in 2013 and Bristol-Myers Squibb was the best performer among large pharmaceutical makers.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.